Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.

IF 1.7 4区医学 Q3 HEMATOLOGY

Acta Haematologica Pub Date : 2023-01-01 Epub Date: 2023-09-12 DOI:10.1159/000533875

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Lingsha Zhou, Sherry Pierce, Zeev Estrov, Hagop Kantarjian, Srdan Verstovsek

{"title":"Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.","authors":"Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Lingsha Zhou, Sherry Pierce, Zeev Estrov, Hagop Kantarjian, Srdan Verstovsek","doi":"10.1159/000533875","DOIUrl":null,"url":null,"abstract":"Introduction: Median duration of therapy with the first JAK1/2 inhibitor ruxolitinib (RUX) approved for patients with intermediate or high-risk myelofibrosis (MF) is about 3 years.Methods: In this retrospective study, we aimed to evaluate clinical features, predictive factors, and outcome of patients presenting to our institution who were able to remain on RUX for ≥5 years (RUX ≥5y, n = 73).Results: Comparing baseline demographics of patients who remained on RUX ≥5y (n = 73) with patients who were on RUX for 6 months to 3 years (n = 203), we confirmed that patients on RUX ≥5y lacked advanced clinical features at the start of therapy, such as anemia, neutropenia, thrombocytopenia, higher blasts or monocytes. Predictive independent factors for staying on RUX ≥5y were hemoglobin >10 g/dL, circulating blasts <1%, platelets >150 × 109/L, neutrophils >70%, and having primary MF. Age over 65 years remained significant for outcome in patients on RUX ≥5y.Conclusion: In this retrospective study, we report on the relevance of absence of advanced clinical features for long RUX therapy and confirm the role of age on outcome despite therapy.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"523-530"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000533875","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Median duration of therapy with the first JAK1/2 inhibitor ruxolitinib (RUX) approved for patients with intermediate or high-risk myelofibrosis (MF) is about 3 years.

Methods: In this retrospective study, we aimed to evaluate clinical features, predictive factors, and outcome of patients presenting to our institution who were able to remain on RUX for ≥5 years (RUX ≥5y, n = 73).

Results: Comparing baseline demographics of patients who remained on RUX ≥5y (n = 73) with patients who were on RUX for 6 months to 3 years (n = 203), we confirmed that patients on RUX ≥5y lacked advanced clinical features at the start of therapy, such as anemia, neutropenia, thrombocytopenia, higher blasts or monocytes. Predictive independent factors for staying on RUX ≥5y were hemoglobin >10 g/dL, circulating blasts <1%, platelets >150 × 109/L, neutrophils >70%, and having primary MF. Age over 65 years remained significant for outcome in patients on RUX ≥5y.

Conclusion: In this retrospective study, we report on the relevance of absence of advanced clinical features for long RUX therapy and confirm the role of age on outcome despite therapy.

查看原文本刊更多论文

服用 Ruxolitinib 5 年或更长时间的骨髓纤维化患者的相关临床因素。

简介首个获批用于中危或高危骨髓纤维化（MF）患者的JAK1/2抑制剂鲁索利替尼（RUX）的中位治疗时间约为3年：在这项回顾性研究中，我们旨在评估在我院就诊的患者中能够坚持服用RUX≥5年（RUX≥5y，n = 73）的患者的临床特征、预测因素和预后：将继续服用RUX≥5年的患者（n = 73）与服用RUX 6个月至3年的患者（n = 203）的基线人口统计学进行比较，我们证实，服用RUX≥5年的患者在开始治疗时缺乏贫血、中性粒细胞减少症、血小板减少症、红细胞或单核细胞增多等晚期临床特征。血红蛋白10 g/dL、循环中血小板1%、血小板150×109/L、中性粒细胞70%以及原发性骨髓纤维化是RUX持续治疗≥5年的独立预测因素。年龄超过65岁对RUX≥5y的患者的预后仍有显著影响：在这项回顾性研究中，我们报告了无晚期临床特征与长期 RUX 治疗的相关性，并证实了年龄对治疗结果的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Haematologica 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.